A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507497-40-00

Acronym

BO42203

Enrollment

Registered

2024-03-07

Start date

2021-05-31

Completion date

2024-05-13

Last updated

2024-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma (DLBCL), Epstein-Barr virus−positive DLBCL, Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026